Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PDE8B | O95263 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27433743 | 0.95 | LMNA (0.47) | LMNAPOLBPDE8BALDH1A1KMT2A | |
| SCHEMBL997818 | 0.89 | EPHX1 (0.43) | LMNAPOLBPDE8BALDH1A1KMT2A | |
| SCHEMBL28992227 | 0.83 | LMNA (0.44) | LMNAPOLBALDH1A1KMT2AMEN1 | |
| SCHEMBL30105359 | 0.82 | LMNA (0.57) | LMNAPOLBALDH1A1 | |
| SCHEMBL14677008 | 0.82 | LMNA (0.57) | LMNAPOLBALDH1A1 | |
| SCHEMBL13195190 | 0.82 | ALDH1A1 (0.41) | LMNAPOLBALDH1A1KMT2AMEN1 | |
| SCHEMBL28992214 | 0.81 | LMNA (0.49) | LMNAPOLBALDH1A1 | |
| SCHEMBL21714157 | 0.79 | ALDH1A1 (0.50) | LMNAPOLBALDH1A1KMT2AMEN1 | |
| SCHEMBL21299980 | 0.79 | LMNA (0.54) | LMNAPOLBALDH1A1KMT2AMEN1 | |
| SCHEMBL12987678 | 0.79 | LMNA (0.40) | LMNAPOLBALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | PDE4A, PDE3A, PDE4B | LMNA 1866/4885POLB 1032/4885PDE8B 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.